• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

HHS: Monkeypox Vaccine Production to Begin in the US as Cases Surpass 14 000

Article
The U.S. Food and Drug Administration published this image of a colorized scanning electron micrograph of monkeypox virus (orange) on the surface of infected VERO E6 cells (green). (©National Institute of Allergy and Infectious Diseases).

Federal health leaders are ramping up the monkeypox vaccine production pipeline as the disease spreads around the United States.

The US Department of Health and Human Services announced an agreement between Bavarian Nordic and Grand River Aseptic Manufacturing (GRAM), a Michigan-based pharmaceutical maker, to make the Jynneos vaccine domestically.

“The Biomedical Advance Research and Development Authority, within the HHS Administration for Strategic Preparedness and Response, has ordered 5.5 million vials of JYNNEOS from Bavarian Nordic to be filled, finished, and delivered from US government-owned bulk vaccine stored in Denmark,” the HHS announcement said. “Under the procurement, Bavarian Nordic agreed to complete a technology transfer that would allow for 2.5 million of those vials to be filled and finished by a US-based contract manufacturer.”


“Under the procurement, Bavarian Nordic agreed to complete a technology transfer that would allow for 2.5 million of those vials to be filled and finished by a US-based contract manufacturer.”


“Rapidly increasing the supply and safe delivery of monkeypox vaccine to those at the highest risk of contracting the virus is a top priority for President Biden,” said Bob Fenton, Coordinator of the White House National Monkeypox Response. “This partnership between Bavarian Nordic and GRAM will significantly increase the capacity to fill and finish government-owned doses – for the first time in the US – and allow us to deliver our current and future supply more quickly to locations nationwide.”

Fenton was the lead speaker August 18 in a press briefing by the White House Monkeypox Response Team.

Starting August 22, an additional 1.8 million doses of vaccine will be available to jurisdictions for ordering.

As of August 18, the United States had 14 115 cases of monkeypox reported in 49 states. The following are among the states with 1000 or more cases according to the latest figures from the US Centers for Disease Control and Prevention:

  • New York 2744
  • California 2663
  • Florida 1372
  • Texas 1079
  • Georgia 1066
  • Wyoming was the last state without a recorded case.

The agency also published updated guidance on obtaining and using Tpoxx (tecovirimat) for treating monkeypoxClinicians and care facility pharmacists requesting the drug should contact state or territorial health departments to obtain it through the jurisdictions where it has been pre-positioned by the Strategic National Stockpile.


Related Videos
"Vaccination is More of a Marathon than a Sprint"
Vaccines are for Kids, Booster Fatigue, and Other Obstacles to Adult Immunization
Interview with Kelly Moore, MD, MPH, president, chief executive officer, Immunization Action Coalition
Related Content
© 2024 MJH Life Sciences

All rights reserved.